Inflammation in COPD

Implications for management

Sanjay Sethi, Donald A. Mahler, Philip Marcus, Caroline A. Owen, Barbara Yawn, Stephen Israel Rennard

Research output: Contribution to journalReview article

45 Citations (Scopus)

Abstract

Chronic obstructive pulmonary disease (COPD) is recognized by the Global Initiative for Chronic Obstructive Lung Disease guidelines as an inflammatory disease state, and treatment rationales are provided accordingly. However, not all physicians follow or are even aware of these guidelines. Research has shown that COPD inflammation involves multiple inflammatory cells and mediators and the underlying pathology differs from asthma inflammation. For these reasons, therapeutic agents that are effective in asthma patients may not be optimal in COPD patients. COPD exacerbations are intensified inflammatory events compared with stable COPD. The clinical and systemic consequences believed to result from the chronic inflammation observed in COPD suggest that inflammation intensity is a key factor in COPD and exacerbation severity and frequency. Although inhaled corticosteroids are commonly used and are essential in asthma management, their efficacy in COPD is limited, with only a modest effect at reducing exacerbations. The importance of inflammation in COPD needs to be better understood by clinicians, and the differences in inflammation in COPD versus asthma should be considered carefully to optimize the use of anti-inflammatory agents.

Original languageEnglish (US)
Pages (from-to)1162-1170
Number of pages9
JournalAmerican Journal of Medicine
Volume125
Issue number12
DOIs
StatePublished - Dec 1 2012

Fingerprint

Disease Management
Chronic Obstructive Pulmonary Disease
Inflammation
Asthma
Disease Progression
Guidelines
Pneumonia
Adrenal Cortex Hormones
Anti-Inflammatory Agents
Pathology
Physicians

Keywords

  • Anti-inflammatory
  • COPD
  • Exacerbation
  • Inflammation

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Sethi, S., Mahler, D. A., Marcus, P., Owen, C. A., Yawn, B., & Rennard, S. I. (2012). Inflammation in COPD: Implications for management. American Journal of Medicine, 125(12), 1162-1170. https://doi.org/10.1016/j.amjmed.2012.06.024

Inflammation in COPD : Implications for management. / Sethi, Sanjay; Mahler, Donald A.; Marcus, Philip; Owen, Caroline A.; Yawn, Barbara; Rennard, Stephen Israel.

In: American Journal of Medicine, Vol. 125, No. 12, 01.12.2012, p. 1162-1170.

Research output: Contribution to journalReview article

Sethi, S, Mahler, DA, Marcus, P, Owen, CA, Yawn, B & Rennard, SI 2012, 'Inflammation in COPD: Implications for management', American Journal of Medicine, vol. 125, no. 12, pp. 1162-1170. https://doi.org/10.1016/j.amjmed.2012.06.024
Sethi S, Mahler DA, Marcus P, Owen CA, Yawn B, Rennard SI. Inflammation in COPD: Implications for management. American Journal of Medicine. 2012 Dec 1;125(12):1162-1170. https://doi.org/10.1016/j.amjmed.2012.06.024
Sethi, Sanjay ; Mahler, Donald A. ; Marcus, Philip ; Owen, Caroline A. ; Yawn, Barbara ; Rennard, Stephen Israel. / Inflammation in COPD : Implications for management. In: American Journal of Medicine. 2012 ; Vol. 125, No. 12. pp. 1162-1170.
@article{208f137fcc024097a54aed2954f9833c,
title = "Inflammation in COPD: Implications for management",
abstract = "Chronic obstructive pulmonary disease (COPD) is recognized by the Global Initiative for Chronic Obstructive Lung Disease guidelines as an inflammatory disease state, and treatment rationales are provided accordingly. However, not all physicians follow or are even aware of these guidelines. Research has shown that COPD inflammation involves multiple inflammatory cells and mediators and the underlying pathology differs from asthma inflammation. For these reasons, therapeutic agents that are effective in asthma patients may not be optimal in COPD patients. COPD exacerbations are intensified inflammatory events compared with stable COPD. The clinical and systemic consequences believed to result from the chronic inflammation observed in COPD suggest that inflammation intensity is a key factor in COPD and exacerbation severity and frequency. Although inhaled corticosteroids are commonly used and are essential in asthma management, their efficacy in COPD is limited, with only a modest effect at reducing exacerbations. The importance of inflammation in COPD needs to be better understood by clinicians, and the differences in inflammation in COPD versus asthma should be considered carefully to optimize the use of anti-inflammatory agents.",
keywords = "Anti-inflammatory, COPD, Exacerbation, Inflammation",
author = "Sanjay Sethi and Mahler, {Donald A.} and Philip Marcus and Owen, {Caroline A.} and Barbara Yawn and Rennard, {Stephen Israel}",
year = "2012",
month = "12",
day = "1",
doi = "10.1016/j.amjmed.2012.06.024",
language = "English (US)",
volume = "125",
pages = "1162--1170",
journal = "American Journal of Medicine",
issn = "0002-9343",
publisher = "Elsevier Inc.",
number = "12",

}

TY - JOUR

T1 - Inflammation in COPD

T2 - Implications for management

AU - Sethi, Sanjay

AU - Mahler, Donald A.

AU - Marcus, Philip

AU - Owen, Caroline A.

AU - Yawn, Barbara

AU - Rennard, Stephen Israel

PY - 2012/12/1

Y1 - 2012/12/1

N2 - Chronic obstructive pulmonary disease (COPD) is recognized by the Global Initiative for Chronic Obstructive Lung Disease guidelines as an inflammatory disease state, and treatment rationales are provided accordingly. However, not all physicians follow or are even aware of these guidelines. Research has shown that COPD inflammation involves multiple inflammatory cells and mediators and the underlying pathology differs from asthma inflammation. For these reasons, therapeutic agents that are effective in asthma patients may not be optimal in COPD patients. COPD exacerbations are intensified inflammatory events compared with stable COPD. The clinical and systemic consequences believed to result from the chronic inflammation observed in COPD suggest that inflammation intensity is a key factor in COPD and exacerbation severity and frequency. Although inhaled corticosteroids are commonly used and are essential in asthma management, their efficacy in COPD is limited, with only a modest effect at reducing exacerbations. The importance of inflammation in COPD needs to be better understood by clinicians, and the differences in inflammation in COPD versus asthma should be considered carefully to optimize the use of anti-inflammatory agents.

AB - Chronic obstructive pulmonary disease (COPD) is recognized by the Global Initiative for Chronic Obstructive Lung Disease guidelines as an inflammatory disease state, and treatment rationales are provided accordingly. However, not all physicians follow or are even aware of these guidelines. Research has shown that COPD inflammation involves multiple inflammatory cells and mediators and the underlying pathology differs from asthma inflammation. For these reasons, therapeutic agents that are effective in asthma patients may not be optimal in COPD patients. COPD exacerbations are intensified inflammatory events compared with stable COPD. The clinical and systemic consequences believed to result from the chronic inflammation observed in COPD suggest that inflammation intensity is a key factor in COPD and exacerbation severity and frequency. Although inhaled corticosteroids are commonly used and are essential in asthma management, their efficacy in COPD is limited, with only a modest effect at reducing exacerbations. The importance of inflammation in COPD needs to be better understood by clinicians, and the differences in inflammation in COPD versus asthma should be considered carefully to optimize the use of anti-inflammatory agents.

KW - Anti-inflammatory

KW - COPD

KW - Exacerbation

KW - Inflammation

UR - http://www.scopus.com/inward/record.url?scp=84869161577&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84869161577&partnerID=8YFLogxK

U2 - 10.1016/j.amjmed.2012.06.024

DO - 10.1016/j.amjmed.2012.06.024

M3 - Review article

VL - 125

SP - 1162

EP - 1170

JO - American Journal of Medicine

JF - American Journal of Medicine

SN - 0002-9343

IS - 12

ER -